Beyond the limits for brain tumor patients
More than 20 000 patients with brain tumors are diagnosed each year in Poland. Too many of those do not have an access to new technologies and high-quality clinical trials that may improve outcomes.
Harat Brain Tumor Research in a partnership with the Franciszek Lukaszczyk Oncology Center is a translational science initiative established by Prof. Marek Harat, Prof. Maciej Harat and Dr. Aleksandra Harat, who focused their experience into moving further a standard of care in brain tumors therapy.
Our Brain Tumor Research central aim is to identify limitations in brain tumor treatment, finding solutions for resistance mechanism and introduce patients to novel treatment paradigms.
Case of complete regression
3 years after the treatment
01
02
03
Our
Affiliations:
Neurooncology and Radiosurgery Department
Neurosurgery
Department
Maciej Harat, MD
Maciej Blok, MD
Arkadiusz Brąszewski, MD Agnieszka Rydzewska, MS
Maciej Blok, MD
Arkadiusz Brąszewski, MD Agnieszka Rydzewska, MS
Neurosurgery
Department
Department
10th Military Clinical Hospital
in Bydgoszcz
Marek Harat, MD
Multidisciplinary
Tumor Board
Tumor Board
Franciszek Lukaszczyk Oncology Center in Bydgoszcz
Maciej Harat, MD
Marek Harat, MD
Michał Marjański, MD
Marek Harat, MD
Michał Marjański, MD
Department
of Oncology
of Oncology
Nicolaus Copernicus University
in Bydgoszcz
Maciej Harat, MD
Our
Team
The multidisciplinary team at the Harat Brain Tumor Center spans the spectrum of specialty investigators, including neurosurgeons, radiation oncologists, clinical oncologists, biostatisticians, neuroscience nurses, clinical trial navigators, program managers, and regulatory specialists.
Dedicate to fight
Brain tumor with us
The Harat Brain Tumor Research has broad experience with industry collaborators ranging from investigators sponored trials to large multicenter clinical trials.
Our multidisciplinary team is leaded by experts in various parts of clinical
research and trials, providing full access to standard of care technologies. Rapid accrual, reliability and experience personnel is what you may expect.
If you represent a technological or
pharmaceutical company that would like to explore a partnership with the Harat Brain Tumor Research center please contact us.
Current trials
TaRRGET:
TTFields and Radiosurgery of Recurrent Glioblastoma +/- 18F-Fluoro-Ethyl-Thyrosine (TaRRGET)
Metis:
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
